Gnubiotics to Present Data at the Annual Meeting of the American Society of Clinical Oncology (ASCO)

On May 27, 2022 Gnubiotics Sciences, a biotech company pioneering immunomodulatory glycopeptides, reported that results from its GLAAD technology program in Colorectal Cancer (CRC) will be presented in a poster presentation at the 2022 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting, scheduled for June 3-7, 2022 in Chicago, Illinois (USA) (Press release, Gnubiotics Sciences, MAY 27, 2022, View Source [SID1234615171]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The poster entitled Exploiting GLAAD molecules to drive an antitumor immune response in a colorectal cancer mouse model will be presented by Yemi Adesokan, Ph.D., Gnubiotics’s Chief Executive Officer, on June 5.

"We are thrilled to present compelling pre-clinical efficacy data in colorectal cancer. These findings nicely complement previous work in melanoma presented earlier this year at AACR (Free AACR Whitepaper). Our Glycopeptides with tumor-associated Antigen and Adjuvant Delivery (GLAAD) technology is designed to drive and boost immune responses directed against various solid tumors and we are excited that the technology continues to deliver promising preclinical data, paving the way for future clinical development. With our collaborators at the University of Zurich we demonstrated that our proprietary glycopeptide candidates were capable to control tumor growth either alone or in combination with existing treatment. We are convinced that glycan-based strategies like our GLAAD approach bear great potential for safe and effective immunotherapies and respond to the urgent need for new modalities for non-responding patients that are otherwise left with few alternative treatments," stated Yemi Adesokan, Ph.D., Gnubiotics’s Chief Executive Officer.

Abstract Title: Exploiting GLAAD molecules to drive an antitumor immune response in a colorectal cancer mouse model.

Abstract Number: 2565

Session Title: Developmental Therapeutics—Immunotherapy

Session Date and Time: Sunday, June 5, 2022, 8:00 AM-11:00 AM CDT

The Poster will also be made available for browsing on the first day of the 2022 ASCO (Free ASCO Whitepaper) Annual Meeting. Viewers will have the possibility to e-mail questions and comments to the presenter.

BeyondSpring Presents New Clinical Data in the Chemotherapy-Induced Neutropenia and NSCLC Programs at the 2022 ASCO Annual Meeting

On May 27, 2022 BeyondSpring Inc. (the "Company" or "BeyondSpring") (NASDAQ: BYSI), a clinical stage global biopharmaceutical company focused on developing innovative cancer therapies to improve clinical outcomes for patients who have a high unmet medical need, reported three poster presentations at the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting being held June 3-7, 2022, in Chicago, Illinois (Press release, BeyondSpring Pharmaceuticals, MAY 27, 2022, View Source;utm_medium=rss&utm_campaign=beyondspring-presents-new-clinical-data-in-the-chemotherapy-induced-neutropenia-and-nsclc-programs-at-the-2022-asco-annual-meeting [SID1234615169]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Presentation highlights:

Chemotherapy-induced neutropenia (CIN): Real-world CMS data showed that week 1 after chemotherapy still presents unmet medical needs with febrile neutropenia (FN) risk, even with prophylactic G-CSF, among patients with breast cancer after high FN–risk chemo
DUBLIN-3 (non-small cell lung cancer, NSCLC): Improved quality of life (QoL) in plinabulin/docetaxel combination vs. docetaxel alone in 2nd/3rd line EGFR-wild type NSCLC patients using the validated EORTC QLQ C30 and QLQ LC13 questionnaires
DUBLIN-3 (NSCLC): Subgroup analysis in patients with non-squamous, EGFR-wild type, 2nd/3rd line NSCLC from the global Phase 3 trial showed a superior survival benefit of 2.6 months in median overall survival (OS) in the plinabulin/docetaxel combination (11.4 months) vs. docetaxel alone (8.8 months), HR=0.75, p=0.023
"We continue to develop plinabulin as a potential ‘pipeline in a drug,’ in both CIN prevention and in NSCLC. We now present ‘real-world’ data demonstrating an unmet medical need with standard of care (SoC) G-CSF for CIN, primarily due to G-CSF’s slow-onset mechanism of action (MoA) that leaves patients unprotected in Week 1 of the chemotherapy cycle. Plinabulin has a fast-onset MoA acting within 24 hours of administration and when combined with G-CSF provided superior CIN protection throughout the entire cycle," said Dr. Ramon Mohanlal, executive vice president, research and development, and chief medical officer, at BeyondSpring. "In terms of the DUBLIN-3 Phase 3 data, patient QoL is an important factor for treatment decisions in 2nd/3rd line NSCLC. The improvement in QoL seen when plinabulin is added to SoC docetaxel vs docetaxel alone could be an important point of product differentiation. Whereas the mOS data in the overall intention to treat (ITT) population was positive, but somewhat modest, we now demonstrate a more robust mOS benefit (of 2.6 months) in a large subgroup of non-squamous 2nd/3rd line NSCLC patients. We continue to work with health authorities on a path to approval in the U.S. and in China."

Dr. Lan Huang, co-founder, chairman and chief executive officer at BeyondSpring, added, "Since we’ve started studying plinabulin, it has continued to show a strong potential to make a difference in a number of oncology indications. We’ve been able to demonstrate repeatedly how it has a two-pronged ability to help prevent CIN and treat cancer directly. We are pleased with the ongoing discussions with China NMPA on the NDA review of the plinabulin and G-CSF combination for the prevention of CIN and plan to file an NDA application to the NMPA for the use of plinabulin in NSCLC by year-end. I’m grateful to our team and partners over the years who have continued to do all the hard work at the bench and in clinical trials to fully understand what plinabulin has to offer for cancer patients. We continue to stay strongly committed to this work in the hopes of bringing plinabulin to patients around the globe."

Title: Real-world effectiveness of prophylactic granulocyte colony-stimulating factor (G-CSF) early (week 1) and late (weeks 2-3) in the cycle for the prevention of febrile neutropenia (FN) among patients (pts) with breast cancer (BC) after high FN–risk chemotherapy (chemo)

Abstract #: 599

Poster Session: Breast Cancer—Local/Regional/Adjuvant
Date/Time: June 6, 2022, 9 AM EDT

Presenter: Douglas W. Blayney, M.D., FASCO, Stanford University

The relative FN risk in Week 1 vs. Weeks 2-3 of the cycle with G-CSF is unknown. It was analyzed compared with no G-CSF in the real-world setting with high FN risk chemotherapy.
Using a CMS database of administrative claims representing 100% of fee-for-service Medicare, an analysis of breast cancer patients who initiated docetaxel (T), doxorubicin (A) or cyclophosphamide (C) monotherapy or combination therapy between 01/01/2015 – 12/31/2019 was performed.
Prophylactic G-CSF was highly effective for the prevention of FN in weeks 2-3 (only 0.8% of patients had FN) but relatively ineffective in Week 1 of cycle 1 (3.2% of patients had FN, which was not different from patients without G-CSF (3.6%)) in the real-world setting. This represents an unmet medical need in Week 1 of the cycle with SoC G-CSF.

Title: DUBLIN-3 results on quality of life (QoL) in second/third-line EGFR-wild type NSCLC patients (pts) receiving docetaxel (Doc) with or without plinabulin (Plin) using the validated EORTC QLQ C30 and QLQ LC13 questionnaires

Abstract #: 9091

Session: Lung Cancer—Non-Small Cell Metastatic
Date/Time: June 6, 2022, 9 AM EDT

Presenter: Trevor Feinstein, M.D., Piedmont Cancer Institute

In the ITT population of the DUBLIN-3 Phase 3 trial, the plinabulin/docetaxel combination had better quality of life versus docetaxel alone in second/third-line EGFR-wild type NSCLC patients (QTWiST, p=0.026).
EORTC QLQ C30 and QLQ LC13 scores were collected at baseline, Day 1 and Day 8 of each cycle.
Mean (SEM) change from baseline in cumulative C30 and LC13 were overall in favor of plinabulin/docetaxel. LC13 items in favor of plinabulin/docetaxel vs docetaxel alone were items 31 (coughing; p<0.05), 36 (sore mouth; p<0.01) and 37 (dysphagia; p<0.01).

Title: Subgroup analysis in patients (pts) with non-squamous (N-Sq), EGFR-wild type (wt), second/third-line NSCLC from the global phase (Ph) 3 trial DUBLIN-3 with the plinabulin/docetaxel (Plin/Doc) combination versus Doc alone

Abstract #: 9090

Session: Lung Cancer—Non-Small Cell Metastatic
Date/Time: June 6, 2022, 9 AM EDT

Presenter: Baohui Han, M.D., Department of Pulmonary Medicine, Shanghai Chest Hospital, Shanghai Jiao Tong University

With PD-1/PD-L1 inhibitors moving to first line in NSCLC, 2nd/3rd line NSCLC represents a severe unmet medical need, dominated by docetaxel-based therapies with >40% severe neutropenia and limited survival.
In the ITT population of the DUBLIN-3 Phase 3 trial, the plinabulin/docetaxel combination had superior efficacy, safety and quality of life versus docetaxel alone in EGFR-wild type, second/third-line NSCLC patients.
In this subgroup analysis of the non-squamous (N-Sq) subgroup, the addition of plinabulin to docetaxel was superior to docetaxel alone for efficacy (mOS 11.4 vs. 8.8 months, HR=0.75, p=0.023) and safety (Grade 4 neutropenia rate 13.9% vs 37.9%, p<0.001).

About DUBLIN-3

The DUBLIN-3 Phase 3 trial is a randomized, single blinded, active-controlled global trial that enrolled 559 patients with 2nd/3rd line NSCLC, EGFR wild type, with a measurable lung lesion. Patients were treated on a 21-day cycle with an infusion of docetaxel (75 mg/m2 on day 1) and plinabulin (30 mg/m2 on days 1 and 8) vs. docetaxel alone (75 mg/m2, day 1). The primary endpoint was overall survival. Secondary endpoints include ORR, PFS, grade 4 neutropenia, 2 year and 3 year OS rate and quality of life analysis. Plinabulin in combination with docetaxel (DP) showed statistically significant overall survival improvements compared to docetaxel alone (D) for the ITT population (DP: n=278; D: n=281).

Enterome to present three abstracts on its novel OncoMimics™ cancer immunotherapies at ASCO 2022

On May 27, 2022 Enterome, a clinical stage biopharmaceutical company developing first-in-class immunomodulatory drugs based on its bacterial Mimicry drug discovery platform, reported the publication of three abstracts related to its OncoMimcs pipeline, including EO2401, its first-in-class off-the-shelf OncoMimics cancer immunotherapy, ahead of poster presentations at the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting, taking place June 3-7, 2022 in Chicago and virtually (Press release, Enterome, MAY 27, 2022, View Source [SID1234615168]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Enterome will present clinical proof-of-concept data from its most advanced OncoMimics drug candidate, EO2401, a therapeutic cancer vaccine candidate currently in clinical development for the treatment of patients with first progression/recurrence of glioblastoma (ROSALIE trial, EOGBM1-18) and for the treatment of patients with locally advanced or metastatic adrenocortical carcinoma, or malignant pheochromocytoma/paraganglioma (SPENCER trial, EOADR1-19).

A third poster describing the Phase 1/2 trial (SIDNEY, EONHL1-20) with Enterome’s second OncoMimics vaccine, EO2463, in non-Hodgkin lymphoma will also be presented at ASCO (Free ASCO Whitepaper).

Details of the poster presentations and session are as follows:

ROSALIE Trial (EOGBM1-18)

Title: EO2401, a novel microbiome-derived therapeutic vaccine for patients with recurrent glioblastoma
Track: Central Nervous System Tumors
Abstract number: #2034
Date and Time: Sunday, June 5, 8:00 AM-11:00 AM CDT
Presenter: Professor Wolfgang Wick, Universitätsklinikum Heidelberg and German Cancer Research Center, Heidelberg, Germany
Authors: Wick, W. et al
SPENCER Trial (EOADR1-19)

Title: EO2401, a novel microbiome-derived therapeutic vaccine for patients with adrenocortical carcinoma (ACC)
Track: Genitourinary Cancer—Kidney and Bladder
Abstract number: #4596
Date and Time: Saturday, June 4, 1:15 PM-4:15 PM CDT
Presenter: Professor Vivek Subbiah, The University of Texas MD Anderson Cancer Center (MDACC), Houston, TX
Authors: Baudin, E. et al
SIDNEY Trial (EONHL1-20)

Title: A novel microbial-derived peptide therapeutic vaccine (EO2463) as monotherapy and in combination with lenalidomide and rituximab, for treatment of patients with indolent non-Hodgkin lymphoma
Poster session: Hematologic Malignancies/Lymphoma and Chronic Lymphocytic Leukemia
Poster number: #TPS7586
Date and Time: Saturday, June 4, 8:00 -11:00 AM CDT
Authors: Zinzani, P.L et al

About OncoMimics Peptides

OncoMimics peptides are gut microbiome-derived peptides that closely mimic antigens expressed by tumor cells. In contrast to tumor antigens, however, OncoMimics peptides are recognized by the immune system as "non-self" and can generate a strong human cytotoxic CD8+ response steming from memory T cells, offering enormous potential to create a new class of cancer vaccines targeting solid and liquid tumors.

Enterome’s pioneering work on its OncoMimics pipeline leverages the fundamental understanding that the gut is the largest lymphoid organ in the body and is home to most of its memory T-cells. As a result, there is constant interaction and presentation of peptides and proteins secreted by gut bacteria to the body’s immune system, resulting in the formation of a pool of effector memory T cells protecting the human body against bacterial invasion. In the event that the bacterial antigens are mimics of tumor antigens, this process leads to the generation of circulating effector memory T cells with a preserved ability to recognize tumor antigens.

Targovax announces publication of the two abstracts accepted for poster presentation at ASCO 2022

On May 27, 2022 Targovax ASA (OSE: TRVX), reported that publication of the two ONCOS-102 abstracts accepted for presentation at the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting 3-7 June 2022 (Press release, Targovax, MAY 27, 2022, View Source [SID1234615167]). The posters will present clinical results from the completed phase 1/2 trials in malignant pleural mesothelioma and in heavily pre-treated, MS-stable colorectal or ovarian cancer with peritoneal metastasis.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

First poster title: Final survival outcomes and immune biomarker analysis of a randomized, open-label, phase I/II study combining oncolytic adenovirus ONCOS-102 with pemetrexed/cisplatin (P/C) in patients with unresectable malignant pleural mesothelioma (MPM)
Session Title: Lung Cancer – Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Time: Monday 6 June 2022, 8:00-11:00 AM CDT, Abstract 8561
Presenter: Dr Santiago Ponce, Medical Oncology, Hospital 12 Octubre, Madrid, Spain

The poster summarizes the overall findings from the completed, randomized phase 1/2 trial in 31 patients with MPM; 20 patients received intra-tumoral (IT) ONCOS-102 in combination with standard of care (SoC) chemotherapy and 11 patients in a control group received SoC chemotherapy only.

In the randomized part of the trial, the 30-month overall survival (OS) rate was 34.3% in the ONCOS-102 treated group (n=14) vs. 18.2% in the SoC-only control group (n=11). In first-line patients, the ONCOS-102 group achieved a median overall survival (mOS) of 25.0 months (n=8) vs. 13.5 months mOS in the SoC-only control group (n=6). The ONCOS-102 first-line mOS compares favorably to SoC historical control studies reporting mOS of 12-16 months1, as well as the combination of nivolumab and ipilimumab which demonstrated mOS of 18.1 months in a phase 3 trial that led to FDA approval2. Tumor biopsy immune cell analyses revealed strong T-cell infiltration induced by ONCOS-102 in patients with partial response (PR) or stable disease (SD), but not in progressors. These observations were confirmed by RNAseq gene expression analysis. The breadth and strength of immune response induced by ONCOS-102 correlated with both tumor response and survival. Further clinical trials in MPM are clearly warranted to validate these positive findings in a larger patient cohort.

Second poster title: Study to evaluate intraperitoneal (IP) ONCOS-102 with systemic durvalumab in patients with peritoneal disease who have epithelial ovarian (OC) or metastatic colorectal cancer (CRC): Phase 2 results
Session Title: Development Therapeutics, Immunotherapy
Time: Sunday 5 June 2022, 8:00-11:00 AM CDT, Abstract 2600
Presenter: Dr Dmitriy Zamarin, Memorial Sloan Kettering Cancer Center, New York, USA

The poster reports clinical data from the ONCOS-102 phase 1/2 combination trial with anti-PD-L1 checkpoint inhibitor durvalumab in heavily pre-treated, MS-stable CRC (n=36) or OC (n=19) with peritoneal metastases. This is a patient population with few treatment alternatives that only offer marginal efficacy and where checkpoint inhibitor monotherapy does not have any meaningful activity. The trial was managed by an external consortium with Ludwig Cancer Research as sponsor, where Targovax was a collaboration partner.

This is the first time ONCOS-102 has been administered IP and in combination with an anti-PD-L1 checkpoint inhibitor. IP delivery of ONCOS-102 was demonstrated to be feasible and well-tolerated, both as monotherapy and in combination with systemic durvalumab. Whereas the initial OC cohort did not meet the efficacy criteria and was closed, the initial CRC cohort met the efficacy criteria and was expanded. In the full CRC cohort (n=36) two patients remained progression free at the end of the study (week 24), but the primary efficacy endpoint of 4 patients remaining progression free at week 24 was not met.

Tumor biopsy immune cell analysis showed increased T-cell infiltration in several patients, confirming that IP administered ONCOS-102 can induce immune activation in heavily pre-treated, immunologically silent solid tumors. Of note, the selected IP dose was the same as used for IT delivery of ONCOS-102 (3×1011 V.P.), although IP delivery is expected to result in lower tumor exposure to the virus relative to IT. Hence, higher doses of IP delivered ONCOS-102 could potentially enhance both the immunological response and clinical activity.

Dr. Lone Ottesen, Chief Medical Officer of Targovax, said: "We are very pleased to have two ONCOS-102 studies accepted for presentation at ASCO (Free ASCO Whitepaper) this year, which is a very important forum to showcase and discuss our clinical data with international experts in the field. In our exploratory clinical program we have now demonstrated that ONCOS-102 can be delivered safely intra-tumorally and intra-peritoneally in combination with PD-1 and PD-L1 checkpoint inhibitors, as well as chemotherapy. Importantly, we have also seen robust immunological and clinical activity in solid tumors of different origins. This gives us confidence to bring ONCOS-102 forward into later stage development, with the first step being a multi-cohort phase 2 trial in PD1-refractory melanoma where we will test several I-O combinations, including the second-generation anti-CTLA4 checkpoint inhibitor botensilimab."

About ASCO (Free ASCO Whitepaper)
American Society of Clinical Oncology Annual Meeting, ASCO (Free ASCO Whitepaper) 2022 will be held in McCormick Place, Chicago, Illinois, United States between 3-7 June 2022.

The 2022 ASCO (Free ASCO Whitepaper) Annual Meeting Program will offer presentations on the latest research in cancer care. This year’s program will feature sessions complementing the meeting’s theme: Advancing Equitable Cancer Care Through Innovation.

Data from SOTIO’s Phase 1/1b AURELIO-03 Trial of SOT101 Demonstrate Clinical Benefit in Patients with Solid Tumors

On May 26, 2022 SOTIO Biotech, a clinical stage immuno-oncology company owned by PPF Group, reported updated interim safety and efficacy data from its Phase 1/1b AURELIO-03 dose escalation study of the IL-2/IL-15 receptor βγ superagonist, SOT101, as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors (Press release, SOTIO, MAY 26, 2022, View Source [SID1234626226]). Data from the study show that SOT101 has a favorable safety profile. The recommended Phase 2 dose was defined at 12 µg/kg SOT101.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The AURELIO-03 study is an open label, single arm Phase 1/1b dose escalation study to determine the recommended Phase 2 dose and to evaluate the preliminary efficacy of SOT101 in patients with advanced solid tumors either as a monotherapy or in combination with pembrolizumab. SOT101 is administered subcutaneously on days 1, 2, 8, and 9 of every three-week cycle. 30 patients were treated on monotherapy dose levels 0.25 to 15 μg/kg and twenty-one patients on combination therapy dose levels 1.5 to 12 μg/kg.

Interim results of SOT101 as a monotherapy demonstrated four patients pretreated with checkpoint inhibitor (CPI) with confirmed stable disease. A partial response was confirmed in one patient with skin squamous cell carcinoma whose tumor was CPI-refractory. The preliminary efficacy is currently being further evaluated in an ongoing monotherapy extension in skin squamous cell carcinoma, melanoma, and renal cell cancer.

In 19 patients with at least one post-baseline tumor assessment across all dose levels who were treated with SOT101 in combination with pembrolizumab, one complete response in a patient with mesothelioma, four partial responses and 10 confirmed stable diseases have been reported.

The adverse event profile of SOT101 in combination with pembrolizumab was in line with the adverse event profile of either compound as monotherapy. No additive toxicity was seen when combining SOT101 with pembrolizumab. For both monotherapy and combination treatment, the recommended Phase 2 dose of SOT101 was established at 12 μg/kg.

This data will be presented by principal investigator Dr. Elena Garralda from the Vall D’Hebron Institute of Oncology, Barcelona, Spain at the 2022 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting in Chicago, Illinois on Saturday, June 4, 2022.

"Despite decades of progress in clinical oncology, the difficulty of treating solid tumors has remained a significant challenge for physicians," said Radek Spisek, M.D., Ph.D., chief executive officer of SOTIO. "Given the promising results from our first-in-human study of SOT101, we are greatly encouraged to have observed excellent preliminary safety and efficacy data both as a monotherapy and in combination with pembrolizumab. We look forward to initiating a basket study of SOT101 in combination with KEYTRUDA to evaluate efficacy and safety in patients with selected advanced or refractory solid tumors. This large Phase 2 AURELIO-04 trial in collaboration with MSD will be initiated in the coming weeks."

Dr. Garralda added: "The patients in this study are some of the hardest to treat, some with up to nine prior lines of therapy, so the clinical benefit observed in the AURELIO-03 study is especially encouraging. These data highlight the potential impact of SOT101 on the treatment landscape for solid tumors."

The presentation from ASCO (Free ASCO Whitepaper) is available below:

ASCO 2022 – AURELIO-03 results.pdf

About SOT101:
SOT101 (SO-C101) is a subcutaneously administered IL-15Rβγ superagonist that is fused to the sushi+ domain of the IL-15 receptor α chain. SOT101 has demonstrated strong preclinical in vivo efficacy in various tumor models showing increased long-term survival and tumor regression, as well as a favorable toxicology profile. SOT101 has been shown in pre-clinical models to synergize with checkpoint inhibitors and antibody therapies exerting ADCC.